6-Bromo-MDMA

6-Bromo-MDMA, also known as 6-bromo-3,4-methylenedioxy-N-methylamphetamine or as 2-bromo-4,5-methylenedioxymethamphetamine, is a psychoactive drug of the phenethylamine, amphetamine, and MDxx families related to MDMA. It does not appear to be a serotonin releasing agent like MDMA, but instead to be a serotonin [reuptake inhibitor] like citalopram, and with much greater serotonin transporter affinity than MDMA. Relatedly, 6-bromo-MDMA lacked key MDMA-like behavioral effects in rodents, including hyperlocomotion, enhanced active [avoidance conditioning], and increased social interaction. The drug was encountered as a novel designer drug in Europe in 2014.